Charlene Moon, NP
Nurse Practitioner · Savannah, GANPI 1457414195
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.1% of the total across 243 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 13 manufacturers reported payments, led by Viiv Healthcare Company at 36.6% of the total. Reporting peaked in 2022 at $1,371 and has fallen 80.5% since, to $268 in 2025. Among nurse practitioner clinicians in GA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 243 payments — averaging $21.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Viiv Healthcare Company$2K
- Gilead$1K
- Johnson & Johnson$655
- Novo Nordisk$324
- Merck$180
- Janssen Products, LP$150
- plus $698 from 7 others
What the payments were for
- Food & beverage$4,97397%
- Education$1503%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Viiv Healthcare Company | 104 | $1,874 |
| Gilead | 63 | $1,242 |
| Johnson & Johnson | 52 | $655 |
| Novo Nordisk | 3 | $324 |
| Merck | 8 | $180 |
| Janssen Products, LP | 2 | $150 |
| Otsuka America Pharmaceutical, Inc. | 1 | $123 |
| Mayne Pharma Commercial LLC | 1 | $121 |
| Amgen | 1 | $115 |
| Neurocrine Biosciences, Inc. | 1 | $112 |
| AstraZeneca | 1 | $109 |
| Theratechnologies Inc. | 5 | $97 |
| Dexcom, Inc. | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,123 in reported general payments places this provider in the 90th percentile of 3,328 nurse practitioner providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| DovatoDolutegravir Sodium/Lamivudine | 127 | $373,972 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 84 | $339,707 |
| TivicayDolutegravir Sodium | 79 | $213,751 |
| JulucaDolutegravir/Rilpivirine | 51 | $179,097 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 49 | $158,423 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 26 | $117,325 |
| DescovyEmtricitabine/Tenofov Alafenam | 58 | $110,185 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 30 | $108,247 |
| PrezcobixDarunavir/Cobicistat | 36 | $85,879 |
| PifeltroDoravirine | 23 | $38,372 |
| JanuviaSitagliptin Phosphate | 22 | $10,848 |
| Atovaquone | 19 | $9,580 |
| Ritonavir | 16 | $2,682 |
| SymbicortBudesonide/Formoterol Fumarate | 12 | $2,643 |
| Ventolin HfaAlbuterol Sulfate | 32 | $1,715 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Viiv Healthcare CompanyDovato, Tivicay, Juluca, Triumeq | $1,874 | $925,243306 claims |
| GileadBiktarvy, Descovy | $1,242 | $449,892142 claims |
| Janssen Products, LPSymtuza | $150 | $117,32526 claims |
| Johnson & JohnsonPrezcobix | $655 | $85,87936 claims |
| MerckPifeltro, Januvia | $180 | $49,22045 claims |
| AstraZenecaSymbicort | $109 | $2,64312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,328 nurse practitioner providers in Georgia.
Other nurse practitioner in Savannah
- Jessica AdkinsSavannah$226K
- Luis PoloSavannah$70K
- Wallette WidenerSavannah$20K
- Angie MoyeSavannah$14K
- Amy CarterSavannah$11K
- Mary RockwellSavannah$9K
- Victor CzerkasijDalton$505K
- Kennon Mc CollumStockbridge$364K
- Tajuana BradleyJohns Creek$256K
- Janice McAlisterAtlanta$221K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.